Open Access Highly Accessed Open Badges Correspondence

Prioritizing investments in innovations to protect women from the leading causes of maternal death

Tara M Herrick*, Claudia M Harner-Jay, Alice M Levisay, Patricia S Coffey, Michael J Free and Paul D LaBarre

Author Affiliations

PATH, PO Box 900922, Seattle, WA 98109, USA

For all author emails, please log on.

BMC Pregnancy and Childbirth 2014, 14:10  doi:10.1186/1471-2393-14-10

Published: 9 January 2014


PATH, an international nonprofit organization, assessed nearly 40 technologies for their potential to reduce maternal mortality from postpartum hemorrhage and preeclampsia and eclampsia in low-resource settings. The evaluation used a new Excel-based prioritization tool covering 22 criteria developed by PATH, the Maternal and Neonatal Directed Assessment of Technology (MANDATE) model, and consultations with experts. It identified five innovations with especially high potential: technologies to improve use of oxytocin, a uterine balloon tamponade, simplified dosing of magnesium sulfate, an improved proteinuria test, and better blood pressure measurement devices. Investments are needed to realize the potential of these technologies to reduce mortality.

Maternal health; Postpartum hemorrhage; Preeclampsia; Eclampsia; Technology assessment; Oxytocin; Magnesium sulfate; Uterine balloon tamponade; Blood pressure measurement; Proteinuria test